The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases.
brain metastases
extra pulmonary neuroendocrine neoplasms
neuroendocrine carcinoma
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
20 07 2022
20 07 2022
Historique:
received:
10
06
2022
revised:
11
07
2022
accepted:
13
07
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Brain metastases (BMs) in patients with extra-pulmonary neuroendocrine neoplasms (EP-NENs) are rare, and limited clinical information is available. The aim of this study was to detail the clinicopathological features, management and outcomes in patients with EP-NENs who developed BMs. A retrospective single-centre analysis of consecutive patients with EP-NENs (August 2004-February 2020) was conducted. Median overall survival (OS)/survival from BMs diagnosis was estimated (Kaplan-Meier). Of 730 patients, 17 (1.9%) had BMs, median age 61 years (range 15-77); 8 (53%) male, unknown primary NEN site: 40%. Patients with BMs had grade 3 (G3) EP-NENs 11 (73%), G2: 3 (20%), G1: 1 (7%). Eight (53%) had poorly differentiated NENs, 6 were well-differentiated and 1 was not recorded. Additionally, 2 (13%) patients had synchronous BMs at diagnosis, whilst 13 (87%) developed BMs metachronously. The relative risk of developing BMs was 7.48 in patients with G3 disease vs. G1 + G2 disease ( BMs in patients with EP-NENs are rare and of increased risk in G3 vs. G1 + G2 EP-NENs. Survival outcomes are poor, and a greater understanding is needed to improve therapeutic outcomes.
Sections du résumé
BACKGROUND
Brain metastases (BMs) in patients with extra-pulmonary neuroendocrine neoplasms (EP-NENs) are rare, and limited clinical information is available. The aim of this study was to detail the clinicopathological features, management and outcomes in patients with EP-NENs who developed BMs.
METHODS
A retrospective single-centre analysis of consecutive patients with EP-NENs (August 2004-February 2020) was conducted. Median overall survival (OS)/survival from BMs diagnosis was estimated (Kaplan-Meier).
RESULTS
Of 730 patients, 17 (1.9%) had BMs, median age 61 years (range 15-77); 8 (53%) male, unknown primary NEN site: 40%. Patients with BMs had grade 3 (G3) EP-NENs 11 (73%), G2: 3 (20%), G1: 1 (7%). Eight (53%) had poorly differentiated NENs, 6 were well-differentiated and 1 was not recorded. Additionally, 2 (13%) patients had synchronous BMs at diagnosis, whilst 13 (87%) developed BMs metachronously. The relative risk of developing BMs was 7.48 in patients with G3 disease vs. G1 + G2 disease (
CONCLUSION
BMs in patients with EP-NENs are rare and of increased risk in G3 vs. G1 + G2 EP-NENs. Survival outcomes are poor, and a greater understanding is needed to improve therapeutic outcomes.
Identifiants
pubmed: 35877265
pii: curroncol29070405
doi: 10.3390/curroncol29070405
pmc: PMC9319979
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5110-5125Références
N Engl J Med. 1999 Aug 12;341(7):476-84
pubmed: 10441603
Ann Oncol. 2013 Jan;24(1):152-60
pubmed: 22967994
Lancet. 2004 May 22;363(9422):1665-72
pubmed: 15158627
Neuroendocrinology. 2017;104(2):105-111
pubmed: 26505990
Am J Surg Pathol. 2008 May;32(5):719-31
pubmed: 18360283
BMC Cancer. 2016 Apr 01;16:260
pubmed: 27037031
J Thorac Dis. 2020 Oct;12(10):6234-6239
pubmed: 33209462
Neuroendocrinology. 2020;110(7-8):688-696
pubmed: 31639796
J Clin Oncol. 2000 Oct 1;18(19):3400-8
pubmed: 11013281
J Neurosurg. 2016 Dec;125(Suppl 1):11-17
pubmed: 27903179
Clin Transl Radiat Oncol. 2021 Dec 02;32:52-58
pubmed: 34926839
N Engl J Med. 2007 Aug 16;357(7):664-72
pubmed: 17699816
J Clin Oncol. 2022 Feb 10;40(5):492-516
pubmed: 34932393
Cancers (Basel). 2021 Mar 12;13(6):
pubmed: 33809007
Neuroendocrinology. 2021;111(11):1111-1120
pubmed: 33227805
Mod Pathol. 2018 Dec;31(12):1770-1786
pubmed: 30140036
Ann Oncol. 2020 Jul;31(7):844-860
pubmed: 32272208
Radiother Oncol. 1998 Jan;46(1):29-32
pubmed: 9488124
J Thorac Oncol. 2013 Sep;8(9):1215-21
pubmed: 23945390
JAMA Oncol. 2020 Jul 1;6(7):1028-1037
pubmed: 32496550
BMC Cancer. 2019 Apr 16;19(1):362
pubmed: 30991982
Eur Arch Otorhinolaryngol. 2016 Oct;273(10):2925-30
pubmed: 26530293
BMC Cancer. 2001;1:5
pubmed: 11432756
Pancreas. 2010 Aug;39(6):799-800
pubmed: 20664477
Clin Transl Oncol. 2019 Jul;21(7):950-953
pubmed: 30506132
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1001-6
pubmed: 10863071
Acta Oncol. 2019 Apr;58(4):499-504
pubmed: 30732516
BMC Endocr Disord. 2020 Apr 3;20(1):44
pubmed: 32245472
Lancet. 2016 Oct 22;388(10055):2004-2014
pubmed: 27604504
Cancer Med. 2019 Dec;8(17):7288-7298
pubmed: 31609098